RT-112细胞

RT112/RT112细胞系/RT112细胞株/RT112人膀胱癌移行细胞

Cell line name RT-112

Synonyms RT 112; RT112

Accession CVCL_1670

Resource Identification Initiative To cite this cell line use: RT-112 (RRID:CVCL_1670)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: TCGA-110-CL cell line panel.

Part of: UBC-40 urothelial bladder cancer cell line index.

Population: Caucasian.

Doubling time: 24 hours (PubMed=3708594); 25 hours (PubMed=25984343); 25.7 hours (PubMed=26055179); 21.6 +- 0.1 hours (PubMed=2144165); ~35 hours (DSMZ=ACC-418).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: CNV analysis.

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: shRNA library screening.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.

Sequence variations

Gene fusion; HGNC; 3690; FGFR3 + HGNC; 11524; TACC3; Name(s)=FGFR3-TACC3 (PubMed=25485619; PubMed=28855393).

Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680; PubMed=31068700).

Mutation; HGNC; 11998; TP53; Simple; p.Ser183Ter (c.548C>G); ClinVar=VCV000634701; Zygosity=Heterozygous (Cosmic-CLP=909704; DepMap=ACH-000473).

Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (Cosmic-CLP=909704; DepMap=ACH-000473).

HLA typing Source: PubMed=26589293

Class I

HLA-A A*26:01,26:01

HLA-B B*08:01,27:05

HLA-C C*01:02,01:02

Class II

HLA-DR DRB1*03:17,15:01

Genome ancestry Source: PubMed=30894373

 

Origin % genome

African 0

Native American 0

East Asian, North 1.6

East Asian, South 0

South Asian 0

European, North 65.6

European, South 32.8

Disease Bladder carcinoma (NCIt: C4912)

Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)

Hierarchy Children:

CVCL_C7JU (RT112 CP1.5) CVCL_2714 (RT112/84) CVCL_6215 (RT112/D21)

CVCL_B7BP (RT112-CP) CVCL_RR17 (RT112rCDDP1000) CVCL_RR18 (RT112rGEMCI20)

Sex of cell Female

Age at sampling Age unspecified

Category Cancer cell line

STR profile Source(s): CLS=300324; Cosmic-CLP=909704; DSMZ=ACC-418; PubMed=11416159; PubMed=25877200; PubMed=27270441

 

Markers:

Amelogenin X

CSF1PO 10 (PubMed=25877200)

10,11 (CLS=300324; Cosmic-CLP=909704; DSMZ=ACC-418; PubMed=27270441)

D2S1338 17,24

D3S1358 15

D5S818 10,13

D7S820 11,12

D8S1179 13,15

D13S317 13,14

D16S539 11,13

D18S51 15 (CLS=300324)

15,17 (DSMZ=ACC-418; PubMed=25877200)

D19S433 13,15

D21S11 27,30

FGA 23 (CLS=300324)

23,25 (DSMZ=ACC-418; PubMed=25877200)

Penta D 10 (DSMZ=ACC-418; PubMed=25877200)

10,11 (CLS=300324)

Penta E 12,16

TH01 7

TPOX 8,11

vWA 14,17

 

Run an STR similarity search on this cell line

PubMed=864752; DOI=10.1093/jnci/58.6.1743

Marshall C.J., Franks L.M., Carbonell A.W.

Markers of neoplastic transformation in epithelial cell lines derived from human carcinomas.

J. Natl. Cancer Inst. 58:1743-1751(1977)

 

PubMed=870558; DOI=10.1177/25.4.870558

Benham F.J., Cottell D.C., Franks L.M., Wilson P.D.

Alkaline phosphatase activity in human bladder tumor cell lines.

J. Histochem. Cytochem. 25:266-274(1977)

 

PubMed=571047

Fogh J.

Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors.

Natl. Cancer Inst. Monogr. 49:5-9(1978)

 

PubMed=6823318; DOI=10.1038/301429a0

O'Toole C.M., Povey S., Hepburn P.J., Franks L.M.

Identity of some human bladder cancer cell lines.

Nature 301:429-430(1983)

 

PubMed=3708594

Masters J.R.W., Hepburn P.J., Walker L., Highman W.J., Trejdosiewicz L.K., Povey S., Parkar M., Hill B.T., Riddle P.N., Franks L.M.

Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines.

Cancer Res. 46:3630-3636(1986)

 

PubMed=2903891; DOI=10.1080/09553008814552341

Peacock J.H., Cassoni A.M., McMillan T.J., Steel G.G.

Radiosensitive human tumour cell lines may not be recovery deficient.

Int. J. Radiat. Biol. 54:945-953(1988)

 

PubMed=2144165; DOI=10.1016/0277-5379(90)90133-e

Walker M.C., Povey S., Parrington J.M., Riddle P.N., Knuechel R., Masters J.R.W.

Development and characterization of cisplatin-resistant human testicular and bladder tumour cell lines.

Eur. J. Cancer 26:742-747(1990)

 

PubMed=7490993; DOI=10.1016/S0140-6736(95)92474-4

Gaetje R., Kotzian S., Herrmann G., Baumann R., Starzinski-Powitz A.

Invasiveness of endometriotic cells in vitro.

Lancet 346:1463-1464(1995)

 

PubMed=8873383; DOI=10.1007/BF00295899

Stadler W.M., Olopade O.I.

The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes.

Urol. Res. 24:239-244(1996)

 

PubMed=11207054; DOI=10.1054/bjoc.2000.1641; PMCID=PMC2363759

Fujiyama C., Jones A., Fuggle S.V., Bicknell R., Cranston D., Harris A.L.

Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion.

Br. J. Cancer 84:558-564(2001)

 

PubMed=11416159; DOI=10.1073/pnas.121616198; PMCID=PMC35459

Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.

Short tandem repeat profiling provides an international reference standard for human cell lines.

Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001)

 

PubMed=11921286; DOI=10.1002/gcc.10050

Williams S.V., Sibley K.D., Davies A.M., Nishiyama H., Hornigold N., Coulter J., Kennedy W.J., Skilleter A., Habuchi T., Knowles M.A.

Molecular genetic analysis of chromosome 9 candidate tumor-suppressor loci in bladder cancer cell lines.

Genes Chromosomes Cancer 34:86-96(2002)

 

PubMed=12127398; DOI=10.1016/S0165-4608(01)00648-3

Strefford J.C., Lillington D.M., Steggall M., Lane T.M., Nouri A.M.E., Young B.D., Oliver R.T.D.

Novel chromosome findings in bladder cancer cell lines detected with multiplex fluorescence in situ hybridization.

Cancer Genet. Cytogenet. 135:139-146(2002)

 

PubMed=15846775; DOI=10.1002/gcc.20166

Williams S.V., Adams J., Coulter J., Summersgill B.M., Shipley J.M., Knowles M.A.

Assessment by M-FISH of karyotypic complexity and cytogenetic evolution in bladder cancer in vitro.

Genes Chromosomes Cancer 43:315-328(2005)

 

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

 

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

 

PubMed=24367658; DOI=10.1371/journal.pone.0084411; PMCID=PMC3867501

Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H., Knowles M.A.

Identification of mutations in distinct regions of p85 alpha in urothelial cancer.

PLoS ONE 8:E84411-E84411(2013)

 

PubMed=24018021; DOI=10.1016/j.eururo.2013.08.052

Allory Y., Beukers W., Sagrera A., Flandez M., Marques M., Marquez M., van der Keur K.A., Dyrskjot L., Lurkin I., Vermeij M., Carrato A., Lloreta J., Lorente J.A., Carrillo-de-Santa-Pau E., Masius R.G., Kogevinas M., Steyerberg E.W., van Tilborg A.A.G., Abas C., Orntoft T.F., Zuiverloon T.C.M., Malats N., Zwarthoff E.C., Real F.X.

Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.

Eur. Urol. 65:360-366(2014)